Cell News and Research

RSS

Final results from C3BS-CQR-1 Phase II trial on heart failure

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces that the final results of its Phase II clinical trial of C3BS-CQR-1 is will be presented at the late breaking clinical trial session at the European Society of Cardiology 2012 Heart Failure Congress in Belgrade, Serbia taking place on May 19-22.

19 May 2012

Positive results from CardioKinetix Parachute system study on heart failure

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced two-year clinical results for the first-of-its-kind catheter-based Parachute Ventricular Partitioning Device, a Percutaneous Ventricular Restoration (PVR) therapy for patients with ischemic heart failure.

19 May 2012

Research demonstrates how a living cell controls its growth process

A collaboration between Lehigh University physicists and University of Miami biologists addresses an important fundamental question in basic cell biology: How do living cells figure out when and where to grow?

19 May 2012

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that an abstract reporting new data from the BiovaxID Phase II mantle cell lymphoma clinical trial conducted by the U.S. National Cancer Institute (NCI) is now available on-line with the significance of these results to be presented by the NCI at the 2012 American Society of Clinical Oncology Annual Meeting.

19 May 2012

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer.

19 May 2012

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago.

19 May 2012

Researchers identify mechanism by which Zds1 protein regulates key function in mitosis

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have identified the mechanism by which protein Zds1 regulates a key function in mitosis, the process that occurs immediately before cell division.

19 May 2012

Screening lung cancer tumor samples for genetic mutations can help tailor personalized treatment

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas — the most common type of non-small cell lung cancer — and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung cancer known as squamous cell carcinoma.

19 May 2012

Promising updates in quest for early detection and treatments for lung cancer

LUNGevity Foundation, the nation's largest lung cancer-focused nonprofit, is pleased to note promising updates in researchers' quest for early detection and treatments for lung cancer during May, Lung Cancer Hope Month.

18 May 2012

Ventac and GIBH announce creation of CASiGEN Pharma

Ventac Partners and the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences (GIBH) today announced the creation of CASiGEN Pharma Ltd. (CASiGEN) to bring new treatments for diabetes and other metabolic disorders to the global market.

18 May 2012

Scientists map how XIAP protein activates vital component of immune defence system

Defects in the gene that encodes the XIAP protein result in a serious immune malfunction. Scientists used biochemical analyses to map the protein's ability to activate vital components of the immune system. Their results have recently been published in Molecular Cell, a journal of international scientific repute.

18 May 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

18 May 2012

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

18 May 2012

Health Canada approves Osiris’ Prochymal to treat acute GvHD in children

Osiris Therapeutics Inc. announced today it has received market authorization from Health Canada to market its stem cell therapy Prochymal (remestemcel-L), for the treatment of acute graft-vs-host disease (GvHD) in children.

18 May 2012

Regular eating times, extended daily fasting may prevent diabetes, obesity

It turns out that when we eat may be as important as what we eat. Scientists at the Salk Institute for Biological Studies have found that regular eating times and extending the daily fasting period may override the adverse health effects of a high-fat diet and prevent obesity, diabetes and liver disease in mice.

18 May 2012

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Active Biotech and Ipsen will present tasquinimod (TASQ), their prostate cancer drug candidate, at the scientific conference "2012 ASCO Annual Meeting" to be held in Chicago (USA) on 1-5 June 2012.

18 May 2012

Effectiveness of 'quorum sensing' directly depends on density of bacterial populations

Scientists at The University of Nottingham have opened the way for more accurate research into new ways to fight dangerous bacterial infections by proving a long-held theory about how bacteria communicate with each other.

18 May 2012

ScreenCell, Affymetrix partner to distribute CTC platform

Affymetrix, Inc. and ScreenCell, a privately-held company, today announced the signing of a worldwide distribution agreement for ScreenCell's isolation devices and dilution buffers, designed for the collection of Circulating Tumor Cells (CTCs) in peripheral blood.

18 May 2012

Dabrafenib drug shrinks tumors in patients with melanoma brain metastases

An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet.

18 May 2012

Researchers identify novel base modification in RNA

Over the past decade, research in the field of epigenetics has revealed that chemically modified bases are abundant components of the human genome and has forced us to abandon the notion we've had since high school genetics that DNA consists of only four bases.

18 May 2012

Cell News and Research

Final results from C3BS-CQR-1 Phase II trial on heart failure

Positive results from CardioKinetix Parachute system study on heart failure

Research demonstrates how a living cell controls its growth process

Biovest announces new data from BiovaxID Phase II mantle cell lymphoma trial

Daiichi Sankyo, ArQule complete enrollment in tivantinib plus erlotinib Phase 3 NSCLC trial

Mount Sinai cancer researchers to present several landmark studies at ASCO meeting

Researchers identify mechanism by which Zds1 protein regulates key function in mitosis

Screening lung cancer tumor samples for genetic mutations can help tailor personalized treatment

Promising updates in quest for early detection and treatments for lung cancer

Ventac and GIBH announce creation of CASiGEN Pharma

Scientists map how XIAP protein activates vital component of immune defence system

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

Health Canada approves Osiris’ Prochymal to treat acute GvHD in children

Regular eating times, extended daily fasting may prevent diabetes, obesity

Ipsen, Active Biotech to present data from tasquinimod phase II trial on CRPC at ASCO 2012

Effectiveness of 'quorum sensing' directly depends on density of bacterial populations

ScreenCell, Affymetrix partner to distribute CTC platform

Dabrafenib drug shrinks tumors in patients with melanoma brain metastases

Researchers identify novel base modification in RNA

How to optimize your cell line development eBook

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest Life Science News